Leuven,
Following the issuance of new shares pursuant to the Capital Commitment entered into with
In addition, by virtue of a downward passive crossing, the following thresholds have been crossed:
- Novartis Pharma AG’s 2,177,226 shares have crossed below the lowest threshold (3%)
Philippe Vlerick /Balderma SA’s 3,580,787 shares have crossed below the lowest threshold (3%)- Thomas M. Clay’s 4,542,110 shares have crossed below the 5% threshold
Content of the latest
Reason of the notification
Acquisition or disposal of voting securities or voting rights
Notifications by
A person that notifies alone
Threshold that is crossed
Downward crossing of the lowest threshold
Denominator
109,075,765
Chain of controlled undertakings through which the holding is effectively held
Not applicable
Notified details
See Annex 1 for this and prior transparency notification of November
Content of the Fidelity Management & Research Company LLC Notification
Reason of the notification
Passive crossing of a threshold
Downward crossing of the lowest threshold
Notifications by
A parent undertaking or a controlling person
Threshold that is crossed
3%
Denominator
109,075,765
Notified details
See Annex 2
Chain of controlled undertakings through which the holding is effectively held
About
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of
For further information please contact:
Chief Executive Officer Tel: +32 16 75 13 10 tom.graney@oxurion.com Chief Business Officer Tel: +32 16 75 13 10 michael.dillen@oxurion.com | US bkurth@conwaycommsir.com ICR Westwicke Tel: +1 617 835 9304 Chris.Brinzey@westwicke.com |
ANNEX 1
Negma notification of
A) Voting rights | Previous notification | After the transaction | |||||
# of voting rights | # of voting rights | % of voting rights | |||||
Holders of voting rights | Linked to securities | Not linked to the securities | Linked to securities | Not linked to the securities | |||
0 | 0 | | - | ||||
0 | 0 | - | |||||
16,250,000 | 0 | - | |||||
Subtotal | 16,250,000 | 0 | + |
B) Equivalent financial instruments | After the transaction | | |||||
Holders of equivalent financial instruments | Type of financial instrument | Expiration date | Exercise period or date | # of voting rights that may be acquired if the instrument is exercised | % of voting rights | Settlement | |
+ | |||||||
TOTAL | 0 | 0.00% |
Thetotals will be updated once you have clicked on
TOTAL (A & B) | # of voting rights | % of voting rights | |
CALCULATE | 0 | 0.00% |
Negma notification of
A) Voting rights | Previous notification | After the transaction | |||||
# of voting rights | # of voting rights | % of voting rights | |||||
Holders of voting rights | Linked to securities | Not linked to the securities | Linked to securities | Not linked to the securities | |||
02/11/2022: | 0 | 15,000,000 | 16.16% | | - | ||
03/11/2022: | 8,828,255 | - | |||||
04/11/2022: | 8,750,000 | - | |||||
7/11/2022: | 0 | - | |||||
Subtotal | 15,000,000 | 16.16% | + | ||||
TOTAL | 15,000,000 | 0 | 16.16% | 0.00% |
B) Equivalent financial instruments | After the transaction | | |||||
Holders of equivalent financial instruments | Type of financial instrument | Expiration date | Exercise period or date | # of voting rights that may be acquired if the instrument is exercised | % of voting rights | Settlement | |
+ | |||||||
TOTAL | 0 | 0.00% |
TOTAL (A & B) | # of voting rights | % of voting rights | |
CALCULATE | 15,000,000 | 16.16% |
ANNEX 2
B) Equivalent financial instruments | After the transaction | | |||||
Holders of equivalent financial instruments | Type of financial instrument | Expiration date | Exercise period or date | # of voting rights that may be acquired if the instrument is exercised | % of voting rights | Settlement | |
Stock Loan | 90,401 | 0.08% | physical | + | |||
TOTAL | 90,401 | 0.08% |
TOTAL (A & B) | # of voting rights | % of voting rights | |
CALCULATE | 3,128,819 | 2.87% |
________
1. Article 14, first paragraph, of the Law of
Attachment
- OXUR Transparency Notifications (EN) 2022.1117
© OMX, source